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studies; the comparison also shows common recent development
of bayesian decision models and choices of appropriate weight-
ing of prior information (e.g. use of mixture prior information
for judging similarity by the “positive treatment effect” in clinical
research or use of different weighting between individual and
population level for the ﬁnancing studies). Moreover, selection of
appropriate weighting in both types of studies face regulators
and ﬁnancing agencies that need to have conﬁdence in the trans-
ferability of their results between regions. CONCLUSIONS:
New developments of statistical analysis especially Bayesian
evaluation both in global clinical research and social sciences can
lead to a better integration of types of research designs. They can
improve scientiﬁc evidence for health care policy decision pro-
cesses. Context free research is not sufﬁcient to integrate the
effect of environmental modiﬁers (like in asthma) or variations in
social and political processes (e.g. variation in exemption criteria
especially during health reforms or systems in transition).
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OBJECTIVE: This study attempted to determine if select patient
and physician demographic variables are predictors of the pre-
scribing of asthma pharmacotherapy in the ambulatory patient
population of the United States, with particular emphasis on the
non-African American minority population. Recent research sug-
gests that these populations may be at-risk for receiving sub-
optimal asthma care due to cultural and/or linguistic barriers to
obtaining proper care, cultural beliefs about asthma treatment,
low socio-economic status and even genetic polymorphisms that
lead to poor responses to asthma medications. METHODS: This
study was a retrospective cross-sectional study that used data
from the National Ambulatory Medical Care Survey (NAMCS)
from 1998 through 2004. The weighted population sample size
of the study was 82,020,318 patients and there were 1,540
observations in this study (pre-weighted sample size). Speciﬁc
patient demographic variables, physician demographic variables
and asthma medications prescribed were extracted from the
dataset and analyzed. RESULTS: A major ﬁnding from this study
was the fact that non-African American minority populations
were receiving sub-optimal asthma pharmacotherapy. Non-
African American minorities (Asians, Native Americans, Paciﬁc
Islanders, Alaskan Natives and other minorities) were less likely
to be prescribed controller medications (OR = 0.405), combina-
tions of ICS and LABA agents (OR = 0.267) and more likely to
be prescribed SABA agents (OR = 1.769) when compared to the
overall population [all p < 0.05]. Additionally, our research also
indicates that these minority patients are generally younger, more
likely to see primary care physicians, and are also likely to have
insurance coverage (public & private). They are also more likely
to reside in an urban area and live in the Western United. States.
CONCLUSION: It appears that a more concerted effort needs
to be undertaken to study the factors that may explain the
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OBJECTIVE: To evaluate the impact of psoriasis (PsO) on the
presence of co-morbidities in the ﬁrst year after the diagnosis.
METHODS: A retrospective study of the PharMetrics database,
compiled from managed care plans throughout the United States,
from January 1, 2000 through December 31, 2006 was con-
ducted. Patients between the ages of 18 to 80 years, who had a
minimum of 12 months of continuous enrollment before and
after their index diagnosis with PsO, were included. The index
diagnosis date was derived from the ﬁrst claim for PsO during the
study period. The presence of co-morbidities was determined by
frequency counts and as a percentage of total claims generated
during the study period. RESULTS: The study cohort included
48,068 patients; 52.3% were females, and the mean age was
46.3 years. Multiple co-morbidities were identiﬁed in the years
prior to and subsequent to the diagnosis of PsO. The ﬁve most
frequently observed co-morbidities were: hypertensive disease
(increased from 24.45% to 26.65%), hyperlipidemia (from
15.72% to 18.06%), pure hypercholesterolemia, pure hyperglyc-
eridemia, and mixed hyperlipidemia (from 14.65% to 16.18%),
diabetes mellitus (from 8.36% to 9.57%), depressive disorder,
episodic mood disorder, and dysthemic disorder (from 6.88% to
7.12%). Additionally, the ﬁve highest percentage increases in
co-morbidities in the years prior to and subsequent to the diag-
nosis of PsO were: 1) Malignant neoplasm of uterus and cervix
uteri (60%, pre-n = 26, post-n = 38); 2) Malignant neoplasm of
trachea, bronchus and lung (57.1%, pre-n = 33, post-n = 54); 3)
Malignant neoplasm of ovary and other uterine adnexa (44.4%,
pre-n = 42, post-n = 63); 4) Psoriatic Arthropathy (44.0%, pre-
n = 1357, post-n = 1950); and 5) Atherosclerosis (33.3%, pre-
n = 142, post-n = 193). CONCLUSION: This study indicates
that co-morbidities increase signiﬁcantly in the year subsequent
to a diagnosis of PsO. The large increases noted in malignancies
may be due to the small numbers of cases observed.
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OBJECTIVE: Five biological treatments are registered for pso-
riasis, the tumor necrosis alpha (TNF-alpha) inhibitor adali-
mumab, etanercept and inﬂiximab and the T-cell modulator
alefacept, efalizumab. Our objectives were to analyse the efﬁcacy
of registered biological drugs in psoriasis and also to compare
their efﬁcacy on a pharmacological group level. METHODS:
Cochrane Highly Sensitive Search Strategy was used to identify
RCTs in MEDLINE. Inclusion criteria were: a) treatment of
psoriasis b) outcome data on the proportions of patients achiev-
ing at least 75% improvement in Psoriasis Area and Severity
Index (PASI) from baseline. The quality of selected studies was
measured using the Jadad-score. Data were entered into Review
Manager 4.2 software. The chosen summary statistic variable
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was the number needed to treat (NNT). Due to lack of face-to-
face evidence on biologics, an indirect comparison of the trials
was conducted, applying the method proposed by Butcher.
RESULTS: Sixteen RCTs involving 7339 patients were identiﬁed.
The active treatment was adalimumab in 1 trial (n = 147),
alefacept in three trials (n = 1289), efalizumab in four trials
(n = 2444), etanercept in four trials (n = 1964) and inﬂiximab in
four trials (n = 1495). All trials were placebo controlled and the
primary follow-up time was 12 weeks. The primary outcome was
PASI75 criteria in all trials. To achieve PASI75, the number of
patients needed to treat (95% conﬁdence intervals) with adali-
mumab 40 mg/eow, alefacept 15 mg, efalizumab 1 mg/kg, etan-
ercept 2 ¥ 50 mg/week and inﬂiximab 5 mg/kg were 2.04 (1.54–
2.94), 5.00 (3.57–7.69), 3.85 (3.13–5.26), 2.27 (2.08–2.50) and
1.32 (1.25–1.39), respectively. Indirect comparisons of TNF-
alpha inhibitors and T-cell modulators yielded the odds ratios of
5.54 (3.65–8.42). CONCLUSION: All biologicals were superior
to placebo, alefacept with the highest and inﬂiximab with the
lowest NNT. TNF-alpha inhibitors were signiﬁcantly superior to
T-cell modulators.
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OBJECTIVE: To compare the effectiveness of Cortisporin and
Ciprodex therapies in the treatment of acute otitis externa (AOE)
in the Louisiana Medicaid population. METHODS: A retrospec-
tive analysis of Louisiana Medicaid data using paid claims from
January 1, 2004, to December 31, 2005, was conducted for
recipients aged 1–64 years. Recipients with an AOE medical
claim (index diagnosis) followed within ﬁve days by a claim for
Ciprodex or Cortisporin were identiﬁed. Any recipients with
dual therapy (deﬁned as greater than one antibiotic or otic
agent), concomitant infection, AOE diagnosis within 30 days
prior to index diagnosis, or other diagnosis warranting antibiotic
therapy within 30 days post index claim were excluded. Each
recipient’s medical and pharmacy claims for 30 days after the
index diagnosis were identiﬁed and evaluated for treatment
failure. Treatment failure was deﬁned as presence of an addi-
tional prescription claim for an antibiotic (oral or otic) or an
antibiotic-steroid combination with or without another medical
AOE claim. The two drug cohorts (Ciprodex and Cortisporin)
were matched using the greedy match technique. Effectiveness,
deﬁned as the proportion of failure patients in each cohort, was
analyzed using the binomial proportion test. RESULTS: The
population consisted predominately of females (55.66%), Cau-
casians (63.49%), and recipients from the New Orleans region
(34.02%). Forty-eight percent of the prescription claims were
written by pediatricians. Each matched cohort had 901 recipients
with average age 10.01 (SD = 6.50) years (Ciprodex), and 10.45
(SD = 7.27) years (Cortisporin). Before propensity score match-
ing, the respective failure rates for Cortisporin and Ciprodex
were 7.47% and 4.69% (p = 0.0009). Within the matched
cohorts, respective failure rates for Cortisporin and Ciprodex
were 6.88% and 4.77% (p = 0.056). CONCLUSION: In the
Louisiana Medicaid population, Cortisporin had a higher failure
rate than Ciprodex for AOE; after propensity score matching the
difference approached statistical signiﬁcance at the 0.05 alpha
level.
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OBJECTIVE: To classify published randomised controlled trials
(RCTs) regarding the comparative efﬁcacy and safety of topical
glaucoma treatment to identify where the evidence lies and the
gaps for future research. METHODS: A systematic search of
MEDLINE, EMBASE, Cochrane Central and conference pro-
ceedings for RCTs recruiting adults with primary open-angle
glaucoma (POAG) and/or ocular hypertension (OH) receiving
any topical medication or placebo. After double-data entry, the
characteristics were analysed with a focus on prostaglandin-
containing trials. RESULTS: We identiﬁed 510 RCTs. Mean
study duration was 15.2 weeks (SD 19.9), with 78% of studies
lasting less than three months. Grouping of studies by duration
and treatment showed that short-term efﬁcacy was available for
all treatments, but RCT evidence of longer-term safety (>12
months) was conﬁned to latanoprost (three trials) and timolol
maleate (two trials) in the monotherapy group and dorzolamide
and timolol in ﬁxed combination (one trial). The majority of
the study population (79.6%) was Caucasian. The data on
co-morbidity was sparse. Of prostaglandins, only latanoprost
reported hypertension as a sub-group. Latanoprost monotherapy
and latanoprost/timolol ﬁxed combination therapy had been
compared with the broadest range of alternative therapies.
Latanoprost alone had been compared with all other classes of
treatments. CONCLUSION: There are extensive RCT data
available for glaucoma treatment. Latanoprost has the most
RCTs and is the only prostaglandin analogue with RCTs over 12
months. Other research methodologies (i.e. observational
studies) have to be considered alongside RCTs to address impor-
tant clinical issues like long-term safety and disease progression.
There is a lack of RCT evidence to explore differential treatment-
effects among subgroups.
SENSORY SYSTEMS DISORDERS—Cost Studies
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OBJECTIVE: Glaucoma has been estimated to affect 2.1% of the
population aged 40 years and over and given the clinical impact
of glaucoma, it is important to evaluate the potential economic
burden of the disease. The aims were to estimate the direct
medical costs of glaucoma in Sweden and also to investigate the
hypothesized cost drivers; intraocular pressure (IOP), amount of
visual ﬁeld damage estimated by the MD, change of MD (ÄMD)
and pseudoexfoliation syndrome (PEX). METHODS: The study
was based on 583 Swedish patients with open-angle glaucoma
and manifest ﬁeld loss followed between 4.5 and 9.25 years.
Data on MD, IOP, PEX, medical resources, and low-vision centre
visits were collected and organized in three-month periods. The
average baseline MD was -11.7 dB and initial values of average
IOP, age were 22.5 mmHg, and 71 years, respectively. All used
resources were multiplied with its respective unit costs to calcu-
late the medical costs for each patient. Cost regressions were
estimated with a multivariate population-averaged panel data
model. RESULTS: Average annual medical cost/patient of glau-
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